Morphometricity as a measure of the neuroanatomical signature of a trait

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th>Citation</th>
<th>Sabuncu, Mert R.; Ge, Tian; Holmes, Avram J.; Smoller, Jordan W.; Buckner, Randy L. and Fischl, Bruce. “Morphometricity as a Measure of the Neuroanatomical Signature of a Trait.” Proceedings of the National Academy of Sciences 113, no. 39 (September 2016): E5749–E5756. © 2016 National Academy of Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1073/pnas.1604378113">http://dx.doi.org/10.1073/pnas.1604378113</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>National Academy of Sciences (U.S.)</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Thu Jan 10 23:02:01 EST 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/108820">http://hdl.handle.net/1721.1/108820</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Morphometricity as a measure of the neuroanatomical signature of a trait

Mert R. Sabuncu1,a,1, Tian Ge2,a,c,d, Avram J. Holmes1,a,e,f, Jordan W. Smoller1,c,d, Randy L. Buckner1,a,b, and Bruce Fischl1,a,b, and the Alzheimer’s Disease Neuroimaging Initiative

1Athinaoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA 02129; 2Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02138; 3Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114; 4Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02138; 5Department of Psychiatry, Yale University, New Haven, CT 06520; 6Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; 7Department of Psychology, Harvard University, Cambridge, MA 02128; and 8Center for Brain Science, Harvard University, Cambridge, MA 02128

Edited by Mark D’Esposito, University of California, Berkeley, CA, and accepted by Editorial Board Member Michael S. Gazzaniga August 1, 2016 (received for review March 16, 2016)

Complex physiological and behavioral traits, including neurological and psychiatric disorders, often associate with distributed anatomical variation. This paper introduces a global metric, called morphometricity, as a measure of the anatomical signature of different traits. Morphometricity is defined as the proportion of phenotypic variation that can be explained by macroscopic brain morphology. We estimate morphometricity via a linear mixed-effects model that uses an anatomical similarity matrix computed based on measurements derived from structural brain MRI scans. We examined over 3,800 unique MRI scans from nine large-scale studies to estimate the morphometricity of a range of phenotypes, including clinical diagnoses such as Alzheimer’s disease, and non-clinical traits such as measures of cognition. Our results demonstrate that morphometricity can provide novel insights about the neuroanatomical correlates of a diverse set of traits, revealing associations that might not be detectable through traditional statistical techniques.

Significance

Neuroimaging has largely focused on two goals: mapping associations between neuroanatomical features and phenotypes and building individual-level prediction models. This paper presents a complementary analytic strategy called morphometricity that aims to measure the neuroanatomical signatures of different phenotypes. Inspired by prior work on heritability, we define morphometricity as the proportion of phenotypic variation that can be explained by brain morphology (e.g., as captured by structural brain MRI). In the dawning era of large-scale datasets comprising traits across a broad phenotypic spectrum, morphometricity will be critical in prioritizing and characterizing behavioral, cognitive, and clinical phenotypes based on their neuroanatomical signatures. Furthermore, the proposed framework will be significant in dissecting the functional, morphological, and molecular underpinnings of different traits.

neuroimaging | brain morphology | statistical association

The structural, functional, and molecular properties of the brain support numerous traits spanning the behavioral, cognitive, and clinical spectra. Neuroanatomical features are in turn influenced by factors such as age, sex, training, and genetics (1–4). Neuroimaging allows us to characterize these bidirectional associations by revealing variation in brain structure and function across individuals. Conventional methods that we use to probe these associations aim to anatomically map effects, build prediction models, or test hypotheses. However, we do not have a standard technique to measure and compare the often spatially distributed and complex patterns of neuroanatomical correlates of different phenotypes. Here we present a metric called morphometricity that offers this capability.

To date, structural neuroimaging studies have primarily relied on three classes of analytic approaches. The first strategy is hypothesis-driven and uses a regression model to examine associations between behavioral traits or clinical conditions and a small number of a priori image-derived measurements, such as those restricted to an anatomical region of interest (ROI) (5). The ROI-based approach provides useful insights about the underlying biology and can be efficient in limited-sample-size scenarios but is restricted to the tested hypothesis. The second approach is exploratory and aims to compute maps of associations by conducting brain-wide tests (6), as exemplified in voxel-based morphometry (7) or vertex-wise cortical thickness analysis (see, e.g., ref. 8). Such massive univariate analyses can offer a comprehensive picture of the underlying anatomical associations, yet they can also be inefficient in revealing subtle, multivariate patterns of association, because each anatomical location is typically examined in isolation and the burden of multiple testing correction can constrain statistical power. The third class includes multivariate techniques such as canonical correlation analysis (9), partial least squares (10), Bayesian inference algorithms (11), or other machine learning methods (12, 13). These studies are focused on either discovering the multivariate patterns of association or demonstrating individual-level prediction capabilities, but the biological interpretation of trained multivariate models can be challenging (14). Furthermore, these methods often suffer from high computational demand and can be sensitive to implementation details, such as the choice of learning rule, optimization algorithm, and local optima in training.

We present morphometricity analysis as an approach to examine the global statistical association between brain morphological and observable traits. Inspired by prior work on trait heritability...


Conflict of interest statement: B.F. has a financial interest in CorticoMetrics, a company whose medical pursuits focus on brain imaging and measurement technologies. His interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI or provided data but did not participate in analysis or writing of this report. (A complete listing of ADNI investigators is available at https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.)

This article is a PNAS Direct Submission. M.D. is a Guest Editor invited by the Editorial Board.

Fees: Free online access through the PNAS open access option.

1To whom correspondence should be addressed. Email: msabuncu@nmr.mgh.harvard.edu

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1604378113/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1604378113

PNAS | Published online September 9, 2016 | E5749-E5756
in population and statistical genetics (15, 16), we define morphometricity as the proportion of phenotypic variation that can be explained by brain morphology (e.g., as captured by measurements derived from structural brain MRI scans). Unlike ROI-based or massive univariate association tests, morphometricity analysis is not concerned with specific anatomical structures or the precise anatomic localization of effects. In contrast to the application of machine learning to population data, the primary aim of morphometricity analysis is not to maximize individual-level prediction accuracy but to examine and quantify statistical associations. The proposed strategy thus affords a unique perspective on the biological underpinnings of different phenotypes and allows us to compare and contrast imaging modalities, types of anatomical measurements, and processing streams.

Morphometricity is grounded in linear mixed effects (LME) modeling, a classical statistical framework that was recently used in population genetics to quantify the heritability of a trait using genome-wide genetic variants (17–19). The model relates the variation in brain morphology computed from brain-wide, MRI-derived measurements to the variation in observable traits and can be fitted using well-established, robust computational tools. In our implementation, we use FreeSurfer (20), a freely available, widely used, and extensively validated brain MRI analysis software package, to automatically process structural MRI scans and obtain a vector of volumetric measurements across subcortical structures and cortical thickness measurements across the entire cortical mantle, which constitute a comprehensive description of the structural neuroanatomy.

We applied the morphometricity analysis to over 3,800 unique brain MRI scans from nine large-scale studies and computed the morphometricity of clinical conditions including Alzheimer’s disease, attention-deficit hyperactivity disorder (ADHD), schizophrenia, autism spectrum disorder, and Parkinson’s disease and nonclinical traits including sex, age, intelligence, education level, and an array of cognitive measures. Our results demonstrate that morphometricity analysis promises to offer a unique perspective on the relationship between brain anatomy and behavioral, cognitive, and physiological traits.

Results

Overview of the Model. The proposed morphometricity analysis is based on the following LME model:

$$y = X\beta + a + \epsilon$$

where $y$ is an $N$-dimensional column vector of a quantitative phenotype with $N$ being the sample size (i.e., number of subjects), $X$ is the (design) matrix of confounding variables (sometimes called covariates or nuisance variables) such as age and sex, $\beta$ is the (fixed effect) coefficient vector, $a \sim N(0, \sigma^2_a K_a)$ is an $N$-dimensional random effect vector drawn from a zero-mean multivariate Gaussian distribution with a covariance matrix that is equal to the scaled anatomic similarity matrix (ASM) $K_a$, and the elements of the noise vector $\epsilon$ are assumed to be drawn from independent and zero-mean Gaussian distributions with homogeneously variance $\sigma^2$. The ASM encodes global morphological resemblance between pairs of individuals in the sample and in principle can be any nonnegative definite matrix with its diagonal elements constrained to be equal to 1 on average, and $\sigma^2$ can thus be interpreted as the total variance captured by the ASM. In this paper, we considered two types of intuitive and widely used metrics that quantify the similarity of volumetric and cortical thickness measurements extracted from structural brain MRI scans between pairs of individuals: (i) a linear similarity metric (i.e., inner product between normalized imaging measurements) and (ii) a nonlinear Gaussian-type similarity metric (Methods). Using a model selection approach, we found that the Gaussian similarity metric provided consistently better description of the data across the traits we studied (Methods and Table S1). Therefore, all reported morphometricity estimates were based on the Gaussian metric.

Formally, we define morphometricity based on the LME model of Eq. 1 as

$$m^2 = \frac{\sigma^2_a}{\sigma^2_a + \sigma^2} = \frac{\sigma^2^2}{\sigma^2}$$

where $\sigma^2$ is the phenotypic variance. Morphometricity is thus the proportion of phenotypic variation that can be explained by brain morphology, the variation of which is captured by the ASM. Estimates of morphometricity can be computed by plugging the restricted maximum likelihood (ReML) estimates (21, 22) of the variance components, $\sigma^2_a$ and $\sigma^2$, into Eq. 2.

We extend this definition to the case-control design, that is, binary disease traits (affected vs. unaffected), using the classical liability-threshold model, which is widely used in population and statistical genetic studies (23, 24). The model assumes that the underlying disease liability (which is a quantitative variable) follows a Gaussian distribution and individuals are cases (affected) if their liability exceeds a threshold. The morphometricity estimate $m^2$ for a disease trait on the observed scale, obtained by fitting the model of Eq. 1 to the binary phenotype data, can be easily transformed to the liability scale (24, 25):

$$m^2 = m^2 K(1 - K) \Phi(\Phi^{-1}(1 - K)) = \frac{m^2 K(1 - K) \Phi(\Phi^{-1}(1 - K))}{\Phi(\Phi^{-1}(1 - K))}$$

where $m^2$ is the morphometricity on the liability scale, $K$ is the prevalence of the disease in the general population (i.e., the proportion of the population having the disease), $P$ is the prevalence of the disease in the study sample, $t = \Phi^{-1}(1 - K)$ is the liability threshold, $\Phi$ is the standard Gaussian cumulative distribution function, and $\Phi$ is the standard Gaussian density function. In real disease studies, cases are often considerably oversampled relative to their population prevalence (known as nonrandom ascertainment), in which case $P$ is larger than $K$. Transforming morphometricity estimates from the observed scale to the liability scale makes them independent of population and sample prevalence and thus comparable across different diseases.

Overview of the Data. We analyzed brain MRI scans and trait data from over 3,800 unique individuals spanning nine large-scale studies: the Harvard/Massachusetts General Hospital Brain Genetic Superstruct Project (GSP) (26), the Human Connectome Project (HCP) (27), the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (28), the Attention-Deficit Hyperactivity Disorder (ADHD 200) sample (29), the Open Access Series of Imaging Studies (OASIS) cross-sectional sample (30), the Center for Biomedical Research Excellence (COBRE) schizophrenia sample (31), the MIND Clinical Imaging Consortium (MCIC) schizophrenia sample (32), the Autism Brain Imaging Data Exchange (ABIDE) (33), and the Parkinson Progression Marker Initiative (PPMI) (34). See Methods for further details on the datasets. The traits of interest were grouped into three categories: clinical diagnoses, general nonclinical traits, and measures of cognition.

Morphometricity of Clinical Diagnoses. The clinical traits we examined included Alzheimer’s disease, ADHD, schizophrenia, autism spectrum disorder, and Parkinson’s disease. Table 1 lists the characteristics of the corresponding samples, along with morphometricity estimates (on the liability scale) and assumed population prevalence values (35–41). Fig. 1 shows the estimated morphometricity values on the liability scale. Our analyses revealed that Alzheimer’s disease is substantially morphometric (with a 95% confidence interval of [0.94–1.00]), suggesting that
this clinical condition is associated with a substantial anatomical signature. However, ADHD, schizophrenia, and autism showed moderate morphometricity values, all greater than 0.35. Finally, we found that Parkinson’s disease was modestly morphometric, with an estimated liability-scale value of 0.20. All examined clinical conditions were statistically significantly associated with whole-brain macroscopic morphology, that is, the estimated morphometricity values were significantly larger than zero (all \( P < 0.005 \)).

Table S2 lists point estimates of morphometricity and their SEs computed via jackknife resampling (42). These results are in strong agreement with the parametric estimates in Table 1.

We had access to two independent samples that allowed us to replicate our morphometricity estimates of Alzheimer’s disease (OASIS) and schizophrenia (COBRE). We observed that there was strong agreement between the estimates from independent samples (Fig. 1). Table S3 provides further data about these replication analyses.

### Morphometricity of General, Nonclinical Traits

The nonclinical traits we examined were age, general intelligence (IQ), sex, and education level. Table 2 lists the characteristics of the samples used in the primary analyses, along with the estimates of morphometricity. These results revealed that all of the examined general traits are significantly and substantially morphometric (Fig. 2); all morphometricity point estimates were greater than 0.8, and all \( P \) values were <1e-8. Table S2 lists morphometricity estimates and their SEs computed via jackknife resampling. These results and the parametric estimates in Table 2 are virtually identical.

We had access to independent replication samples for all of the general nonclinical traits we examined. It can be seen in Fig. 2 that the replication analyses revealed remarkably consistent morphometricity estimates. Table S4 provides further data about these replication analyses.

### Contrasting with ROI-Based Association Analyses

The most common analytic strategy in today’s neuroimaging studies involves examining associations between traits and measurements from ROIs. Our goal in this analysis was to contrast the proposed whole-brain morphometricity analysis with such ROI-based techniques. We restricted our analysis to the six phenotypes (age, IQ, sex, education, Alzheimer’s disease, and schizophrenia), for which we had two independent datasets. We then used one of the samples (the replication sample in the analyses above) for the discovery of the most significantly associated ROI with the trait and the other sample (the primary sample in the analyses above) to quantify the strength and magnitude of association. Table S5 lists the structures that exhibited the strongest association with the traits in the discovery analysis.

Fig. 3 visualizes the magnitude of association between the ROI-based measurements and phenotypic variation, assessed using the same LME modeling framework of whole-brain morphometricity. Here, we replaced the global ASM with one computed based on ROI measurements (see Methods for further details). It can be seen that the proportion of variance explained by ROI-based measurements was consistently lower than whole-brain morphometricity estimates (with general intelligence exhibiting the smallest discrepancy). Most notably, for education and schizophrenia, ROI-based associations were much weaker (both in magnitude and statistical significance) than whole-brain associations (Fig. 3 and Table S5). In fact, education and schizophrenia did not exhibit a statistically significant correlation with individual ROI-based measurements, whereas whole-brain morphometricity analyses revealed significant associations.

### Morphometricity Analysis of Cognitive Measures

We used the most recent release of the HCP data (downloaded on December 15, 2015) to compute morphometricity estimates for an array of cognitive measures. Our primary analysis relied on 190 non-twin subjects of non-Hispanic European ancestry (28.9 ± 3.8 y of age, 47.3% female) drawn from separate families (i.e., there were no siblings in this sample). Fig. 4 shows the morphometricity estimates computed for variables that measure sustained attention, nonverbal and verbal episodic memory, working memory, executive function, delay discounting, language (vocabulary comprehension and reading decoding), spatial orientation, processing speed, fluid intelligences (and self-regulation (impulsivity)). We conducted a secondary (replication) analysis on 208 non-Hispanic white twins (29.4 ± 3.2 y of age, 61.4% female), with one twin drawn from each family, and thus there were no siblings in this replication sample. Fig. 4 shows the results obtained from this secondary analysis as well.

Our results demonstrated that all examined variables, except for the measure of self-regulation, are statistically significantly morphometric. We note further that there was an important amount of variability in the degree of morphometricity across cognitive measures. This variation was remarkably consistent between the primary and secondary analyses. Measures of attention, cognitive flexibility, working memory, verbal episodic memory, and inhibition were substantially morphometric (with estimates greater than 0.80
in both primary and secondary analyses). Measures of language, nonverbal episodic memory, spatial orientation, processing speed, and fluid intelligence were moderately morphometric (with point estimates greater than 0.50).

Discussion

Morphometricity: A Metric to Quantify Whole-Brain Associations with a Trait. In this paper, we introduced a technique for analyzing the neuroanatomical underpinnings of various clinical, physiological, and behavioral traits using large-scale neuroimaging data. In contrast with association testing techniques widely used in today’s neuroimaging studies, our approach does not focus on a priori ROIs or conduct independent (massive univariate) interrogations at each candidate region or voxel. Instead, morphometricity is a global quantification of the whole-brain anatomical signature of a trait.

Although the proposed approach is intimately related to image-based multivariate prediction performance, there are two characteristics of morphometricity that make it different from the application of machine learning. First, the metric does not require cross-validation, which is often the technique used in machine learning to gauge prediction accuracy. Cross-validation is usually computationally demanding and relies on the unbiased setting of model parameters (which might be achieved via a nested cross-validation strategy) and repeated and balanced partitioning of data into train and test sets. In contrast, the proposed LME-based approach exploits the entire dataset to fit the model and estimate the unknown variance component parameters, and in turn morphometricity, in an unbiased fashion. Second, morphometricity is a classical statistical measure of explained variance and is therefore familiar to interpret.

Morphometricity has many parallels to heritability in genetics (15, 16). Both concepts, statistical in nature, are about phenotypic variation and the proportion of variance explained. Thus, the interpretation has to be carried out within a probabilistic framework, is limited by the studied population, depends on the technique used to quantify the trait, and can be confounded by unmeasured variables acting through unknown mechanisms. The biases due to confounds such as (cryptic) relatedness between subjects or population admixture are well-studied in heritability analysis. As we elaborate below, morphometricity alone cannot be used to infer causal relationships but has to be followed up with further studies that will home in on potential mechanisms. The core difference between morphometricity and heritability is the direction of association. In heritability, this direction is known and fixed, because there is no known biological mechanism that would allow the phenotype to alter the genotype. In morphometricity, however, the directionality can go either way and has to be dissected with further biological studies.

Traits Can Be Morphometric to Different Degrees. Virtually all traits we examined in this study were significantly morphometric. However, our analyses also revealed interesting variation in the whole-brain anatomical signature of different traits. Certain phenotypes, such as Alzheimer’s disease, age, and (maybe surprisingly) general intelligence (IQ), were substantially morphometric (with estimates exceeding 0.90), whereas other measures, such as nonverbal episodic memory, spatial orientation, processing speed, and fluid intelligence exhibited moderate morphometricity. Furthermore, the psychiatric disorders we examined (schizophrenia, ADHD, and autism) were all moderately morphometric, unequivocally pointing to a neuroanatomical substrate for these clinical conditions. The proposed morphometricity analysis is the first coherent framework that enables us to directly quantify and compare the morphological signatures of such diverse sets of traits.

The traits we presented in this study have been examined extensively in prior structural neuroimaging studies to reveal morphological correlates. Whereas many of these studies relied on regional or voxel-level association tests that are conducted at each location independently, there is growing evidence that multiple brain regions are implicated in complex, multivariate relationships with many common phenotypes. For example, patterns of atrophy in neurodegenerative conditions such as Alzheimer’s disease have been shown to spread through large-scale, distributed brain networks that can be circumscribed based on resting-state activity (43). Furthermore, developmental mechanisms such as neuronal migration, synapse formation, myelination, and synaptic pruning follow predictable and robust spatiotemporal patterns that are likely associated with behavioral traits such as intelligence and disrupted in psychiatric disorders such as schizophrenia (44, 45). Our data from ROI-based analyses support the premise of analyzing brain-wide patterns, rather than isolated regions, for associations between neuroanatomical features and behavioral or clinical phenotypes.

Morphometricity Estimates Are Consistent Across Independent Samples. For most of the traits we examined in this study we replicated our analyses on independent data. All point estimates fell within 95% confidence intervals of the estimates computed on the corresponding independent data. These results suggested that the presented morphometricity estimates are consistent across different samples. We present these results with a cautionary note, however.

Table 2. Sample characteristics and morphometricity estimates for the analyzed general nonclinical traits

<table>
<thead>
<tr>
<th>Trait name</th>
<th>Sample size</th>
<th>Age (mean ± SE) (minimum–maximum)</th>
<th>Females, %</th>
<th>Study name</th>
<th>Trait (mean ± SE) (minimum–maximum)</th>
<th>Morphometricity estimate</th>
<th>SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1,073</td>
<td>22 ± 5.8 (18–81)</td>
<td>56</td>
<td>GSP</td>
<td>1.00</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>IQ</td>
<td>155</td>
<td>11.3 ± 2.0 (7.2–17.7)</td>
<td>60</td>
<td>ADHD</td>
<td>110.9 ± 14.4 (73–144)</td>
<td>0.95</td>
<td>0.05</td>
</tr>
<tr>
<td>Sex</td>
<td>1,074</td>
<td>25.3 ± 13.7 (18–84)</td>
<td>50</td>
<td>GSP</td>
<td>0.93</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td>152</td>
<td>60.4 ± 11.4 (30–82)</td>
<td>34.8</td>
<td>PPMI</td>
<td>16.1 ± 2.8 (9–24)</td>
<td>0.81</td>
<td>0.08</td>
</tr>
</tbody>
</table>

N/A, not applicable.

Fig. 2. Morphometricity estimates of general nonclinical traits computed using the Gaussian ASM of Eq. 5. IQ denotes general intelligence. Each bar is annotated with study names used to compute these estimates. Blue bars correspond to results from the primary analyses, whereas purple bars correspond to independent replication analyses. Error bars indicate SE of the estimates.
As we emphasized above, morphometricity is a statistical metric that depends on the studied population and the measurement of the trait. Thus, variations in the patient composition, for example, or changes in diagnostic criteria will inevitably lead to different estimates of morphometricity. In our replication analyses, these factors seemed to play only a minor role.

Whole-Brain Morphometricity Analyses Can Be More Powerful Than ROI-Based Analyses. We present morphometricity analysis as an alternative to the classical region-based interrogation conducted in neuroimaging, which is often focused on discovering or characterizing biomarkers and mapping biological effects. The central challenge in region-based approaches is that we need to either confine our analyses to a priori ROIs or exhaust statistical power by probing a large number of candidate regions. In our experiments, we conducted a direct comparison between whole-brain morphometricity analysis and an ROI-based approach. To identify trait-specific ROIs, a discovery analysis was run on independent samples of each trait. The associations between the identified ROIs and traits were then tested in nonoverlapping samples. Identifying the most associated ROI and estimating the magnitude of association in independent samples avoided the issue of circular analysis (46, 47) and produced unbiased morphometricity estimates for individual ROIs. Our results demonstrated that whole-brain morphology consistently explained more of the phenotypic variation than single ROIs. Furthermore, morphometricity analysis could reveal associations that were not detectable when focused on isolated regions. For example, education and schizophrenia were found to be not significantly associated with volumetric/thickness measurements of any of the individual ROIs, yet both traits were moderately and significantly morphometric in whole-brain analyses, which indicates that they may have spatially distributed neuroanatomical signatures that cannot be captured by individual ROIs. In addition, whole-brain morphometricity analysis offers the capability of capturing interactions between brain regions and thus can be more powerful than analyzing each ROI independently.

Potential Limitations and Drawbacks of Morphometricity. Morphometricity is a statistical metric and assumes a particular, linear model of the relationship between variables. One critical component of the model is the ASM, which captures the covariance structure of the random effect that accounts for the morphological variation in the sample. In this work, we considered a linear metric and a nonlinear Gaussian-type metric to quantify the similarity of volumetric/thickness measurements between pairs of subjects and used a model selection technique to find the metric that better describes the data. Our analyses suggest that the Gaussian metric is consistently better than the linear metric across the traits we studied and captures a significant portion of relevant intersubject variation under different conditions. However, we have not attempted to exhaustively explore other types of similarity metrics, which may emphasize different aspects of the data and produce different results. Alternatively, the ASM can be built using a bottom-up approach and expressed as a combination of elementary matrices, and the parameters of this combination can be treated as unknown variables. By increasing the unknowns in the model, however, this approach will likely reduce statistical power.

Another important point to consider is that ASM should reflect brain-wide global morphology and cannot be optimized for a specific trait. This latter observation is critical to be able to objectively compare morphometricity estimates across different traits. Our global definition of ASM and morphometricity, however, constrains the interpretation of the results. Certain traits with very dramatic
yet focal effects might not yield large morphometricity estimates, because the proposed model is insensitive to localized effects. Finally, as in any association testing framework, the interpretation of morphometricity analysis results should be done very carefully and consider confounding mechanisms. This is well understood in the context of heritability, where nongenetic (e.g., dietary, cultural, and socioeconomic) influences that vary across racial groups or families can confound genetic analyses. Similar drawbacks apply to morphometricity. For example, siblings might have similar brain morphologies and phenotypic expressions, yet there might not be any causal link between brain morphology and the phenotype. Therefore, we recommend running morphometricity analyses on a set of unrelated subjects. Furthermore, we advise constraining the analysis (if possible) to a homogeneous sample of uniform ancestry and explicitly controlling for other potential confounding factors, such as age, sex, and scan site.

Potential Uses and Extensions of Morphometricity. Morphometricity analysis can be used to prioritize imaging modalities, acquisition parameters, and processing pipelines. For example, there are a growing number of software packages that allow us to automatically extract numerous structural measurements from brain images. Different constructions of feature vectors and different metrics that quantify the similarity of imaging features between individuals will result in distinct ASMs, which can be compared with the model selection framework used in this study. Therefore, morphometricity analysis offers a way to quantitatively and objectively identify the imaging features and intersubject similarity metric that best describe the trait-relevant aspects of whole-brain morphology.

Alternatively, one can imagine estimating the functional, structural, connectomic, and molecular signatures of a trait within a single statistical model, where each of these components is represented with a random effect and the corresponding similarity matrix computed from a relevant modality. Similarly, one can partition the phenotypic variation into contributions from, for instance, cortical and subcortical features, or different large-scale brain networks. This strategy might offer novel insights about the neural correlates of certain phenotypes by integrating multiple modalities and/or modeling spatial heterogeneity in a unified analytic framework. This novel perspective might also allow us to quantify the complementary information contained in different imaging modalities and spatial locations.

As longitudinal imaging studies continue to grow, it will be interesting to extend morphometricity to examine the relationships between temporal dynamics in brain morphology (e.g., global atrophy rates) and clinical or behavioral traits. We envision using the LME strategy to model longitudinal data (48, 49), and we will define the morphometricity of longitudinal changes in phenotypes within this framework.

Finally, the proposed framework can also offer a novel perspective on examining relationships between different phenotypes. We plan to extend morphometricity, which is essentially the degree of association between global brain morphology and a phenotype, to quantify the “morphological correlation” between phenotypes. This will be analogous to genetic correlation analysis (50), which quantifies the genetic overlap between traits. We believe that morphological correlation will be an invaluable tool to examine the complex biological relationships between the various dimensions of human behavior and will inform basic and translational research into exploring and redefining the landscape of brain diseases.

Methods

The Imaging Measurements. In this study we used the extensively studied FreeSurfer-derived measurements to describe the whole-brain morphology. The imaging measurements included volumes of noncortical structures (51) (left and right cerebral white matter, lateral ventricle, inferior lateral ventricle, cerebellum white matter, cerebellum cortex, thalamus proper, caudate, putamen, pallidum, hippocampus, amygdala, and the third and fourth ventricles) and thickness measurements of cortical regions (52) (left and right superior frontal, rostral middle frontal, caudal middle frontal, pars opercularis, pars triangularis, pars orbitalis, lateral orbitofrontal, medial orbitofrontal, precentral, paracentral, frontal pole, superior parietal, inferior parietal, supr marginal, post central, precuneus, superior temporal, middle temporal, inferior temporal, banks of the superior temporal sulcus, fusiform, transverse temporal, entorhinal, temporal pole, parahippocampal, lateral occipital, lingual, cuneus, pericalcarine, rostral anterior frontal, caudal anterior frontal, posterior parietal, isthmus parietal, and insula).

The Anatomical Similarity Matrix. The ASM plays a central role in the proposed morphometricity analysis. The ASM is an $N 	imes N$ symmetric matrix, where $N$ is the number of subjects in the analyzed sample. Entries in the ASM quantify the pairwise global similarity between the brain morphologies of two individuals. In principle, the ASM can be any nonnegative definite matrix with its diagonal elements constrained to be equal to 1 on average. In this study, we considered two widely used similarity metrics (linear and Gaussian) to construct the ASM.

Assume that $V_s$ denotes the $k$-th imaging measurements from subject $i$. $M$ is the total number of measurements, and $s_i$ is the sample SD of the $k$-th measurement. The first ASM we considered uses a linear kernel. Thus, the similarity is measured as the linear correlation between pairs of imaging vectors and the $(i,j)$-th entry is computed as

$$1 \sum_{k} \frac{V_{s_i}(k) V_{s_j}(k)}{s_i^2}$$

This is equivalent to modeling the random effect $a$ in Eq. 1 as a linear combination of the imaging features: $a = \mathbf{Z} \mathbf{a}$, where $Z$ is an $N \times M$ matrix comprising the standardized imaging measurements (i.e., the $(i,k)$-th entry of $Z$ is $V_{s_i}/s_i$), and $\mathbf{a}$ is an $M \times 1$ random vector distributed as $a - N(0, \sigma^2 a^2 / M)$ (i.e., each imaging measurement is associated with an independent and normally distributed effect size). The covariance of $a$ can then be computed as $\sigma^2 a^2 \mathbf{Z}^T / M$, that is, $\mathbf{Z}^T / M$ is the ASM with its entries explicitly stated in Eq. 4.

The second ASM we considered was computed using a Gaussian kernel on standardized imaging features, with the $(i,j)$-th entry defined as

$$\exp \left( - \frac{(V_{s_i}(k) - V_{s_j}(k))^2}{2 \sigma^2 k} \right).$$

Note that each ASM definition corresponds to different models of trait-relevant variation. For example, the Gaussian kernel can capture nonlinear and multivariate associations between brain morphology and traits. One can further decide to weigh different features differently, based on, for example, some a priori information about trait relevance. Each of these ASM choices will correspond to a particular semiparametric regression model, where the morphological association is captured with a function that belongs to a specific space of functions induced by the used kernel (53). Below, we describe an empirical strategy to choose the most appropriate ASM model from a selection of candidates.

In the presented study, for a given similarity metric, we computed an ASM for the cortical thickness measurements and an ASM for the head-size-normalized volumes of noncortical structures (i.e., divided by total intracranial volume estimates). The global ASM was then computed as the average of the cortical and noncortical ASMs.

Model Selection. To select the ASM that can best describe the data, we used a model selection technique derived for LME models and proposed in ref. 53. Specifically, for a given ASM $K_s$, if we denote $V = \sigma^2 K_s + \sigma^2 I$ as the REML estimate of the covariance of $\mathbf{y}$, $V = \mathbf{V}^T \mathbf{V}$, $\mathbf{V}^T \mathbf{X}$, and $\mathbf{X}^T \mathbf{V}$, and define $S = 1 - \sigma^2 \mathbf{y}^T \mathbf{y}$, it can be shown that $tr(S)$, that is, the trace of the matrix $S$, is a measure of model complexity. Liu et al. (53) thus proposed the following Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) in the LME modeling framework:

$$\text{AIC} = \log(\text{RSS}) + 2tr(S), \quad \text{BIC} = \log(\text{RSS}) + \log(N) \cdot tr(S),$$

where $\text{RSS} = (y - \hat{y})^T (y - \hat{y}) = \sigma^2 (N - tr(S))$ is the residual sum of squares of the LME model. Both AIC and BIC reward the goodness of fit (the first term) of the model and penalize complex models (the second term) to avoid overfitting. BIC has a larger penalty term than AIC for large $N$ and thus favors simpler models. We selected the ASM that gave smaller AIC/BIC values.

The Analysis Pipeline. We first ran FreeSurfer on all structural brain MRI scans available in each of the analyzed studies and dropped the subjects that
Given individual-level data and the ASM, we fit the model of Eq. 1 to estimate the variance component parameters via the ReML algorithm (21, 22). In MATLAB, we implemented an efficient Fisher scoring method to iteratively maximize the restricted likelihood of the model. The SE of the variance component estimates can be derived using the inverse of the Fisher information matrix when the algorithm converges. Empirically we confirmed the parametric estimates using jackknife resampling (Table S2). Significance of the morphometricity estimate was obtained via a likelihood ratio test comparing LME models with and without the random effects. Because the null hypothesis (σ² = 0) lies on the boundary of the parameter space, the likelihood ratio test statistic follows a half-normal distribution with all probability mass at zero (S4). Implementations of the developed morphometricity tools are available at people.cscs.mit.edu/sabuncumorphometricity.

ROI-Based Morphometricity Analysis. To compare the proposed whole-brain morphometricity analysis to more conventional ROI-based analyses, we implemented an ROI-based adaptation of Eq. 1. Here, instead of computing the ASM using an array of variables that span the brain, we computed ROI-based ASMs only using a single ROI biomarker: the variable that had the strongest association with the trait of interest. To identify the ROI biomarker of each trait, we conducted an independent discovery analysis on a non-overlapping sample, examining the association between each of the candidate imaging variables and the trait in a regression analysis while appropriately controlling for age, sex, and site. The imaging variable that exhibited the smallest P value was then identified as the ROI biomarker for the trait of interest and used in the morphometricity analysis. We note that for the ROI-discovery analyses we used the replication (secondary) samples of the whole-brain morphometricity analysis. This way, we computed the ROI-based morphometricity results using the primary samples.

The Data. All of the data analyzed in this study have been made publicly available and are described in detail in prior publications (28–34, 55). As explained in these references, the data collection efforts have been approved by pertinent institutional committees and all subjects have received appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites. We used baseline brain MRI scans (T1-weighted acquired on 1.5T machines), clinical diagnosis, and demographic variables from phase 1 of the ADNI (28). In the ADHD 200 sample (29), cases were defined as those with evidence of nontypical development and an ADHD-Combined diagnosis, as appropriate informed consent. We obtained access to these data following the relevant procedures outlined in corresponding data dissemination websites.